News Trends, News Analysis, News Archive.



Hot Topics Related To `mn-166`

In Internet Explorer versions up to 8, things inside the canvas are inaccessible!

News Timeline

10 Articles About mn-166

companyNews reuters.com

BRIEF-Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALS

* MEDICINOVA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS

companyNews reuters.com

BRIEF-MediciNova completes enrollment in the phase 2 trial of MN-166 in methamphetamine dependence

* MediciNova announces the completion of enrollment in the phase 2 clinical trial of MN-166 (ibudilast) in methamphetamine dependence

companyNews reuters.com

BRIEF-MediciNova says exploratory interim clinical outcomes data from clinical trial of MN-166 in ALS

* Says it announced exploratory interim clinical outcomes data from clinical trial of MN-166 (ibudilast) in ALS presented at the American Academy of Neurology (AAN) 69th Annual Meeting in Boston

governmentFilingsNews reuters.com

BRIEF-Medicinova announces positive findings on MN-166 (ibudilast) in alcohol dependence

* Medicinova announces publication of positive findings on MN-166 (ibudilast) in alcohol dependence

governmentFilingsNews reuters.com

BRIEF-MediciNova announces phase 2b trial of MN-166 (ibudilast) in progressive MS will continue as planned following DSMB review of interim efficacy analysis

* MediciNova announces phase 2b trial of MN-166 (ibudilast) in progressive MS will continue as planned following DSMB review of interim efficacy analysis

companyNews reuters.com

BRIEF-MediciNova announces exploratory interim clinical outcomes data from clinical trial of MN-166 (ibudilast)

* MediciNova announces exploratory interim clinical outcomes data from clinical trial of MN-166 (ibudilast) in ALS presented at the 27th international symposium on ALS/MND in Dublin, Ireland

companyNews reuters.com

BRIEF-Medicinova says FDA granted orphan drug designation to MN-166 for ALS

* Medicinova announces FDA granted orphan drug designation to MN-166 (ibudilast) for amyotrophic lateral sclerosis

rbssHealthcareNews reuters.com

BRIEF-Medicinova starts interim efficacy analysis in phase 2b trial of MN-166

* Medicinova announces initiation of interim efficacy analysis in phase 2b trial of MN-166 (ibudilast) in progressive MS

companyNews reuters.com

BRIEF-Medicinova announces interim data from clinical trial of MN-166 (ibudilast) in ALS

* Announces interim data from clinical trial of MN-166 (ibudilast) in ALS presented at the American Academy of Neurology (AAN) 68th annual meeting in Vancouver, Canada

companyNews reuters.com

BRIEF-FDA grants fast track designation for Medicinova's drug for progressive multiple sclerosis

* FDA grants fast track designation for Medicinova's MN-166 (ibudilast) for progressive multiple sclerosis Source text for Eikon: Further company coverage: